Literature DB >> 24445518

Cervical cancer in 2013: Screening comes of age and treatment progress continues.

Chris J L M Meijer1, Peter J F Snijders1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24445518     DOI： 10.1038/nrclinonc.2013.252

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  From ASCO-gynaecological cancer: Advances in cervical cancer screening and treatment.

Authors:  Rebecca Kirk
Journal:  Nat Rev Clin Oncol       Date:  2013-06-18       Impact factor: 66.675

2.  A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer.

Authors:  Michael Herfs; Yusuke Yamamoto; Anna Laury; Xia Wang; Marisa R Nucci; Margaret E McLaughlin-Drubin; Karl Münger; Sarah Feldman; Frank D McKeon; Wa Xian; Christopher P Crum
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-11       Impact factor: 11.205

3.  Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of low-grade squamous intraepithelial lesions.

Authors:  Michael Herfs; Carlos Parra-Herran; Brooke E Howitt; Anna R Laury; Marisa R Nucci; Sarah Feldman; Cynthia A Jimenez; Frank D McKeon; Wa Xian; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2013-09       Impact factor: 6.394

4.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.

Authors:  Dorien C Rijkaart; Johannes Berkhof; Lawrence Rozendaal; Folkert J van Kemenade; Nicole W J Bulkmans; Daniëlle A M Heideman; Gemma G Kenter; Jack Cuzick; Peter J F Snijders; Chris J L M Meijer
Journal:  Lancet Oncol       Date:  2011-12-14       Impact factor: 41.316

5.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

Authors:  Guglielmo Ronco; Paolo Giorgi-Rossi; Francesca Carozzi; Massimo Confortini; Paolo Dalla Palma; Annarosa Del Mistro; Bruno Ghiringhello; Salvatore Girlando; Anna Gillio-Tos; Laura De Marco; Carlo Naldoni; Paola Pierotti; Raffaella Rizzolo; Patrizia Schincaglia; Manuel Zorzi; Marco Zappa; Nereo Segnan; Jack Cuzick
Journal:  Lancet Oncol       Date:  2010-01-18       Impact factor: 41.316

Review 6.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Authors:  Marc Arbyn; Guglielmo Ronco; Ahti Anttila; Chris J L M Meijer; Mario Poljak; Gina Ogilvie; George Koliopoulos; Pontus Naucler; Rengaswamy Sankaranarayanan; Julian Peto
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

7.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.

Authors:  Guglielmo Ronco; Joakim Dillner; K Miriam Elfström; Sara Tunesi; Peter J F Snijders; Marc Arbyn; Henry Kitchener; Nereo Segnan; Clare Gilham; Paolo Giorgi-Rossi; Johannes Berkhof; Julian Peto; Chris J L M Meijer
Journal:  Lancet       Date:  2013-11-03       Impact factor: 79.321
  7 in total
  11 in total

1.  Effects of DCK knockdown on proliferation, apoptosis and tumorigenicity in vivo of cervical cancer HeLa cells.

Authors:  Q-Y Shang; C-S Wu; H-R Gao
Journal:  Cancer Gene Ther       Date:  2017-08-18       Impact factor: 5.987

2.  LINC01133 promotes the progression of cervical cancer by sponging miR-4784 to up-regulate AHDC1.

Authors:  Yan Feng; Luyun Qu; Xiuli Wang; Chunyan Liu
Journal:  Cancer Biol Ther       Date:  2019-08-07       Impact factor: 4.742

Review 3.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

4.  Inhibitor of β-catenin and TCF (ICAT) promotes cervical cancer growth and metastasis by disrupting E-cadherin/β-catenin complex.

Authors:  Yayun Jiang; Wei Ren; Weijia Wang; Jing Xia; Liyao Gou; Mengyao Liu; Qun Wan; Lan Zhou; Yaguang Weng; Tongchuan He; Yan Zhang
Journal:  Oncol Rep       Date:  2017-09-18       Impact factor: 3.906

5.  Up-regulated lncRNA XIST contributes to progression of cervical cancer via regulating miR-140-5p and ORC1.

Authors:  Xing Chen; Dongsheng Xiong; Liya Ye; Kai Wang; Lingfei Huang; Shuangshuang Mei; Jinhong Wu; Shanshan Chen; Xiaoli Lai; Lingzhi Zheng; Meifen Wang
Journal:  Cancer Cell Int       Date:  2019-02-28       Impact factor: 5.722

6.  MicroRNA-708 Suppresses Cell Proliferation and Enhances Chemosensitivity of Cervical Cancer Cells to cDDP by Negatively Targeting Timeless.

Authors:  Xinwei Zou; Chenjie Zhu; Lin Zhang; Yi Zhang; Fengqing Fu; Youguo Chen; Jinhua Zhou
Journal:  Onco Targets Ther       Date:  2020-01-09       Impact factor: 4.147

7.  LINC00885 promotes cervical cancer progression through sponging miR-3150b-3p and upregulating BAZ2A.

Authors:  Yeling Liu; Jingrui Chen; Lizhong Zhou; Chunhua Yin
Journal:  Biol Direct       Date:  2022-01-10       Impact factor: 4.540

8.  MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3.

Authors:  Zhongyi Fan; Hanzhi Cui; Xiaojie Xu; Zhi Lin; Xuelin Zhang; Lei Kang; Baiyu Han; Jing Meng; Zhifeng Yan; Xiang Yan; Shunchang Jiao
Journal:  Oncotarget       Date:  2015-09-22

9.  E6 hijacks KDM5C/lnc_000231/miR-497-5p/CCNE1 axis to promote cervical cancer progression.

Authors:  Yan Zhang; Xing Li; Jun Zhang; Lin Mao
Journal:  J Cell Mol Med       Date:  2020-08-20       Impact factor: 5.310

10.  LINC00707 Regulates miR-382-5p/VEGFA Pathway to Enhance Cervical Cancer Progression.

Authors:  Hua Guo; Jing Li; Furong Fan; Ping Zhou
Journal:  J Immunol Res       Date:  2021-06-29       Impact factor: 4.818
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.